nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Access versus evidence: The regulators’ dilemma
|
Schilsky, Richard L |
|
2018 |
15 |
3 |
p. 240-242 |
artikel |
2 |
A new modeling and inference approach for the Systolic Blood Pressure Intervention Trial outcomes
|
Yang, Song |
|
2018 |
15 |
3 |
p. 305-312 |
artikel |
3 |
Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST)
|
Nigrovic, Peter A |
|
2018 |
15 |
3 |
p. 268-277 |
artikel |
4 |
Beyond total treatment effects in randomised controlled trials: Baseline measurement of intermediate outcomes needed to reduce confounding in mediation investigations
|
Landau, Sabine |
|
2018 |
15 |
3 |
p. 247-256 |
artikel |
5 |
Expedited and facilitated drug evaluations and evidence of benefit and risk: The cup is half-full
|
Califf, Robert M |
|
2018 |
15 |
3 |
p. 235-239 |
artikel |
6 |
Expedited approval programs at the Food and Drug Administration
|
Begg, Colin B |
|
2018 |
15 |
3 |
p. 217-218 |
artikel |
7 |
Expediting drug development for serious illness: Trade-offs between patient access and certainty
|
Woodcock, Janet |
|
2018 |
15 |
3 |
p. 230-234 |
artikel |
8 |
Increasing the use of mobile technology–derived endpoints in clinical trials
|
Herrington, William G |
|
2018 |
15 |
3 |
p. 313-315 |
artikel |
9 |
LIBERTI: A SMART study in plastic surgery
|
Hibbard, Jonathan C |
|
2018 |
15 |
3 |
p. 286-293 |
artikel |
10 |
Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: A systematic review
|
Yelland, Lisa N |
|
2018 |
15 |
3 |
p. 278-285 |
artikel |
11 |
Reporting non-adherence in cluster randomised trials: A systematic review
|
Agbla, Schadrac C |
|
2018 |
15 |
3 |
p. 294-304 |
artikel |
12 |
The reporting of harms in publications on randomized controlled trials funded by the “Programme Hospitalier de Recherche Clinique,” a French academic funding scheme
|
Favier, Romain |
|
2018 |
15 |
3 |
p. 257-267 |
artikel |
13 |
The US Food and Drug Administration’s expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation
|
Wallach, Joshua D |
|
2018 |
15 |
3 |
p. 243-246 |
artikel |
14 |
The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements
|
Wallach, Joshua D |
|
2018 |
15 |
3 |
p. 219-229 |
artikel |